



Sheet 1 of

RECEIVED
NOV 05 2003
TECH CENTER 1600/2900

| | | | |
|---|--|--------------------------------------|---------------------------|
| FORM PTO-1449 | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO.: CV01379K | SERIAL NO.: 10/057,640 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | APPLICANT: Harry R. Davis, et al. | |
| | | FILING DATE: January 25, 2002 | GROUP: 1614 |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE |
|----------------------|----|--------------------|----------|-----------------|-------|---------------|-------------------------------|
| SW | AA | 5,021,461 | 06/04/91 | Robinson et al. | | | |
| SW | AB | 4,687,777 | 08/18/87 | Meguro et al. | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES NO |
|----|----|--------------------|----------|---------|-------|---------------|-----------------------|
| SW | AC | WO 97/28149 | 08/07/97 | PCT | | | |
| | AD | WO 99/22728 | 05/14/99 | PCT | | | |
| | AE | WO 01/96347 | 12/20/01 | PCT | | | |
| | AF | WO 02/26729 | 04/04/02 | PCT | | | |
| | AG | WO 02/064094 | 08/22/02 | PCT | | | |
| | AH | WO 95/35277 | 12/28/95 | PCT | | | |
| | AI | WO 02/50027 | 06/27/02 | PCT | | | |
| | AJ | WO 02/50060 | 06/27/02 | PCT | | | |
| | AK | WO 02/50068 | 06/27/02 | PCT | | | |
| | AL | WO 99/08501 | 02/25/99 | PCT | | | |
| | AM | WO 94/26738 | 11/24/94 | PCT | | | |
| | AN | EP 1 036 563 A1 | 09/20/00 | EPO | | | |
| | AO | EP 0 753 298 A1 | 01/15/97 | EPO | | | |
| SW | AP | FR 1103113 | 10/31/55 | FRANCE | | | X (abs.) |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|----|----|--|
| SW | AQ | Stuart B. Rosenblum et al., Discovery of 1-(4-Fluorophenyl)-(3R)-(3-(fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption, <i>J. Med. Chem.</i> 41:973-980 (1998) |
| | AR | Gilbert R. Thompson et al., Novel lipid-regulating drugs, <i>Exp. Opin. Invest. Drugs</i> 9(11):2619-2628 (2000) |
| | AS | T. Kosoglou et al., Coadministration of Ezetimibe and Fenofibrate Leads to Favorable Effects on Apo CIII and LDL Subfractions, <i>Atherosclerosis</i> 2:89 (2001) |
| | AT | Harry R. Davis et al., The Synergistic Hypocholesterolemic Activity of the Potent Cholesterol Absorption Inhibitor, Ezetimibe, in Combination With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Dogs, <i>Metabolism</i> 50 (10):1234-1241 (2001) |
| | AU | Study Showed Ezetimibe Significantly Reduced Levels of LDL Cholesterol or "Bad" Cholesterol in Patients, Schering-Plough Press Release |
| | AV | T. Kosoglou et al., Pharmacodynamic Interaction Between Fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe, <i>Atherosclerosis</i> (2):38 (2001) |
| | AW | Remington's Pharmaceutical Sciences, 18 th ed. 1990 p. 1319, 1633-1647 |
| | AX | Baker S G et al., Treatment of homozygous familial hypercholesterolaemia with probucol, <i>South African Medical Journal</i> (1982) |
| SW | AY | R. Milanese et al., Xantom E Ipercolesterolemia: Prevalenza, Diagnosi e Terapia, <i>Chron. Derm.</i> 455-61 (1990) |

| | |
|-------------------------|---------------------------------|
| EXAMINER S. Wang | DATE CONSIDERED 12/09/02 |
|-------------------------|---------------------------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

CV01379K

APPLICATION NO.:

10/247,646

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPLICANT:

HARRY R. DAVIS et al.

FILING DATE:

01/25/2002

GROUP:

1614

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE |
|----------------------|----|--------------------|------|------|-------|---------------|-------------------------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES | NO |
|--|----|--------------------|------|---------|-------|---------------|--------------------|----|
| | AL | | | | | | | |
| | AM | | | | | | | |
| | AN | | | | | | | |
| | AO | | | | | | | |
| | AP | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | | | | | | | |
|----|----|--|--|--|--|--|--|--|
| SW | AQ | T. Kosoglou et al., "CoAdministration of Simvastatin and Ezetimibe Leads to Significant Reduction in LDL-Cholesterol", Proceedings of 3 rd International Congress on Coronary, Artery Disease from Prevention to Intervention, Lyon, France p. 71 (2000), XP008027568 | | | | | | |
| | AR | | | | | | | |
| | AS | | | | | | | |
| | AT | | | | | | | |
| | AU | | | | | | | |
| | AV | | | | | | | |

EXAMINER

S. Wang

DATE CONSIDERED

12/8/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.